Ezz Life Science Holdings Ltd. · ASX:EZZ
Ezz Life Science — Investor Presentation (June 2025)
12 slides from Ezz Life Science's investor presentation, Jun 19, 2025
Slide 1: ShareCafe 'Sip & Learn' Presentation
For personal use only ShareCafe ‘Sip & Learn’ Presentation 19 June 2025 Glenn Cross, Non-Executive Chair
Slide 2: Disclaimer
DISCLAIMER For personal use only This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below. This document is not a
Slide 3: About EZZ
About EZZ For personal use only The EZZ Mission To become a leading life science company improving quality of life and human health by accelerating innovation to market. EZZ develops, distributes and markets 63 SKUs scientifically formulated products under the EZZ brand to seven countries and region
Slide 4: Product Development Process
Product Development Process For personal use only 8 1 Post-Market Consumer Monitoring Insights 7 2 Global Product Distribution Conceptu -alisation Product Development Lifecycle Manufac Formulation turing Development 6 3 Regulatory Scientific Approval Validation 5 4 ASX: EZZ 4 Investor Presentation 1
Slide 5: Product Portfolio
Product Portfolio For personal use only We formulate, produce, market and distribute health We are an exclusive distributor of skin care supplements under the brand of EZZ. Our deep products under the EÁORON brand in Australia understanding of our target consumers allows us to and New Zealand to pha
Slide 6: Extensive and Growing Distribution Channels
Extensive and Growing Distribution Channels For personal use only In 1H FY25 EZZ added 14 new independent pharmacy stores to our expanding omnichannel distribution network Chemists Specialist and Grocery Retailers E-commerce Platforms 600+ 200+ 750+ ASX: EZZ 6 Investor Presentation 1H FY2025
Slide 7: Financial Highlights Q1 to Q3 FY25
Financial Highlights Q1 to Q3 FY25 For personal use only Cash on Hand Receipts from Customers Operating Cash Flows $2.9M $21.1M $45.8M No external debt Up 4% on PCP Up 73% on PCP at 30 March 2025 Sales during the 2024 11.11 Global Dividend Gross Margin Shopping Festival 77%* $5.9M 2 cents Interim FY
Slide 8: Our Expanding Global Reach
Our Expanding Global Reach For personal use only Markets Entered Australia, China, Vietnam, Singapore, Kuwait, New Zealand Confirmed New Markets United States, Thailand Markets Under Exploration Japan, Turkey, Malaysia ASX: EZZ 8 Investor Presentation 1H FY2025
Slide 9: Southeast Asia Expansion
Southeast Asia Expansion For personal use only New 3-Year ROFA Covers $21M Minimum Entry into Thailand, Distribution All Local Costs Purchase Vietnam & Singapore Deal with ROFA (marketing, logistics, Commitment under the EZZ brand Enterprises distribution) EZZ Retains Exclusivity: No Partner with 10
Slide 10: US Market Entry Update
US Market Entry Update For personal use only Achieved FDA registration Amazon store launch and and commenced US-based influencer-led marketing Introduced new US-focused manufacturing, supporting Launched EZZ Day Shopify campaigns scheduled to roll brand, EZZ Day, featuring four supply chain resilien
Slide 11: Q&A
For personal use only Q&A ASX: EZZ 11 Investor Presentation 1H FY2025
Slide 12: Contact
EZZ Life Science Holdings Limited EZZLifescience For personal use only ASX: EZZ linkedin.com/company/e zz-life-science-holdings EZZAustralia Contact EZZ Life Science Holdings Limited ABN 83 608 363 604 EZZ_Australia 1/55-59 Parramatta Road Lidcombe NSW. 2141 T: 02 9160 2305 E: ir@ezzlife.com.au www.
EZZ Life Science Holdings — Investor Presentation (June 2025) on 6ix